Clinical Trials Logo

Pancreas Adenocarcinoma clinical trials

View clinical trials related to Pancreas Adenocarcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06381882 Not yet recruiting - Pancreas Cancer Clinical Trials

The Role of the Human Microbiome in Patients After Pancreatic Resection.

MiPac
Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to classify patients that undergo pancreatic resection for presumed pancreatic or periampullary malignancy into high and low risk groups for postoperative complications based on longitudinal saliva, rectal/faecal, tumor, blood and/or bile microbiome profiles. To identify the dynamics of the microbiome, as well as the possibly related short-term and long-term complications, multiple samples at different timepoints are needed from the patients.

NCT ID: NCT06110598 Not yet recruiting - Pancreas Cancer Clinical Trials

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

- This study is being done to find out if extending adjuvant chemotherapy for patients by giving additional chemotherapy can lengthen the amount of time before their cancer comes back. The additional chemotherapy is called capecitabine. - Capecitabine is an oral drug (taken by mouth). It is approved by the US Food and Drug Administration (FDA) for adjuvant treatment of adults with pancreatic cancer and also for the treatment of other types of cancer